- Home
- ADXN vs CVKD Comparison
ADXN vs CVKD Comparison
Compare ADXN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- CVKD
- Stock Information
- Founded
- ADXN 2002
- CVKD 2022
- Country
- ADXN Switzerland
- CVKD United States
- Employees
- ADXN N/A
- CVKD N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- ADXN Health Care
- CVKD Health Care
- Exchange
- ADXN Nasdaq
- CVKD Nasdaq
- Market Cap
- ADXN 8.5M
- CVKD 27.0M
- IPO Year
- ADXN N/A
- CVKD 2023
- Fundamental
- Price
- ADXN $10.95
- CVKD $13.70
- Analyst Decision
- ADXN
- CVKD Strong Buy
- Analyst Count
- ADXN 0
- CVKD 1
- Target Price
- ADXN N/A
- CVKD $32.00
- AVG Volume (30 Days)
- ADXN 20.4K
- CVKD 28.0K
- Earning Date
- ADXN 11-21-2025
- CVKD 11-06-2025
- Dividend Yield
- ADXN N/A
- CVKD N/A
- EPS Growth
- ADXN N/A
- CVKD N/A
- EPS
- ADXN N/A
- CVKD N/A
- Revenue
- ADXN $210,347.00
- CVKD N/A
- Revenue This Year
- ADXN $86.57
- CVKD N/A
- Revenue Next Year
- ADXN N/A
- CVKD N/A
- P/E Ratio
- ADXN N/A
- CVKD N/A
- Revenue Growth
- ADXN N/A
- CVKD N/A
- 52 Week Low
- ADXN $6.51
- CVKD $8.74
- 52 Week High
- ADXN $12.05
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- ADXN 62.51
- CVKD 51.56
- Support Level
- ADXN $8.53
- CVKD $13.51
- Resistance Level
- ADXN $9.51
- CVKD $14.35
- Average True Range (ATR)
- ADXN 0.74
- CVKD 0.49
- MACD
- ADXN 0.05
- CVKD -0.07
- Stochastic Oscillator
- ADXN 71.51
- CVKD 33.07
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.